[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ID30237A - KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES - Google Patents

KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Info

Publication number
ID30237A
ID30237A IDW00200101612A ID20011612A ID30237A ID 30237 A ID30237 A ID 30237A ID W00200101612 A IDW00200101612 A ID W00200101612A ID 20011612 A ID20011612 A ID 20011612A ID 30237 A ID30237 A ID 30237A
Authority
ID
Indonesia
Prior art keywords
insulin
fbpase
obstacles
plants
combination
Prior art date
Application number
IDW00200101612A
Other languages
English (en)
Indonesian (id)
Inventor
Mark D Erion
Paul Van Poelje
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of ID30237A publication Critical patent/ID30237A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IDW00200101612A 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES ID30237A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
ID30237A true ID30237A (id) 2001-11-15

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101612A ID30237A (id) 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Country Status (25)

Country Link
EP (1) EP1143955B1 (fr)
JP (1) JP2003515523A (fr)
KR (3) KR20070046210A (fr)
CN (3) CN1714866A (fr)
AT (1) ATE300288T1 (fr)
AU (1) AU771039B2 (fr)
BR (1) BR9917005A (fr)
CA (1) CA2354053A1 (fr)
CZ (1) CZ20012353A3 (fr)
DE (1) DE69926400T2 (fr)
DK (1) DK1143955T3 (fr)
ES (1) ES2246586T3 (fr)
HK (1) HK1046863B (fr)
HU (1) HUP0402506A3 (fr)
ID (1) ID30237A (fr)
IL (2) IL143569A0 (fr)
MX (1) MXPA01006511A (fr)
NO (1) NO20013115L (fr)
NZ (1) NZ512219A (fr)
PL (1) PL352756A1 (fr)
PT (1) PT1143955E (fr)
RU (2) RU2227749C2 (fr)
SK (1) SK9172001A3 (fr)
WO (1) WO2000038666A2 (fr)
ZA (1) ZA200105016B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
WO2001047935A2 (fr) 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Promedicaments a base de bisamidate phosphonate
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
CA2412142A1 (fr) * 2000-07-06 2002-01-17 Metabasis Therapeutics, Inc. Combinaison d'inhibiteurs de fbpase et d'agents antidiabetiques utile pour le traitement du diabete
WO2002040458A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
WO2003095665A2 (fr) 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Procede d'elaboration de promedicaments cycliques de pmea et de pmpa
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
WO2004022083A1 (fr) * 2002-09-04 2004-03-18 Dsm Ip Assets B.V. Composition nutritionnelle et therapeutique d'agent sensibilisant a l'insuline et de fraction peptidique
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2515726C (fr) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazoles
EP1700856B1 (fr) * 2003-12-26 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Derive de thiazole
BRPI0514372A (pt) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase
EP1857118A1 (fr) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Composition medicinale pour le traitement du diabete
CA2591416A1 (fr) * 2004-12-15 2006-06-22 Daiichi Sankyo Company Limited Composition medicinale contenant un inhibiteur de la fbpase
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
WO2008063842A2 (fr) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (fr) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
DK0427799T3 (da) * 1989-01-24 1995-05-08 Gensia Inc Fremgangsmåde og forbindelser til indgivelse af AICA-ribosid og til nedsættelse af blodglucose
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1998039342A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
HK1046863A1 (en) 2003-01-30
PL352756A1 (en) 2003-09-08
CN101164618A (zh) 2008-04-23
DK1143955T3 (da) 2005-11-14
KR100689943B1 (ko) 2007-03-08
IL143569A (en) 2006-06-11
NO20013115D0 (no) 2001-06-21
ATE300288T1 (de) 2005-08-15
EP1143955A3 (fr) 2002-08-28
SK9172001A3 (en) 2002-04-04
AU771039B2 (en) 2004-03-11
CN1714866A (zh) 2006-01-04
EP1143955B1 (fr) 2005-07-27
ES2246586T3 (es) 2006-02-16
KR20060114724A (ko) 2006-11-07
HUP0402506A3 (en) 2007-05-29
MXPA01006511A (es) 2004-03-19
WO2000038666A3 (fr) 2001-11-29
KR20010099942A (ko) 2001-11-09
CA2354053A1 (fr) 2000-07-06
RU2227749C2 (ru) 2004-04-27
NO20013115L (no) 2001-08-24
NZ512219A (en) 2004-12-24
CN100352505C (zh) 2007-12-05
HUP0402506A2 (hu) 2005-04-28
BR9917005A (pt) 2002-04-02
CN1350466A (zh) 2002-05-22
EP1143955A2 (fr) 2001-10-17
AU2058300A (en) 2000-07-31
KR20070046210A (ko) 2007-05-02
JP2003515523A (ja) 2003-05-07
PT1143955E (pt) 2005-11-30
DE69926400T2 (de) 2006-05-24
DE69926400D1 (de) 2005-09-01
WO2000038666A2 (fr) 2000-07-06
CZ20012353A3 (cs) 2001-12-12
IL143569A0 (en) 2002-04-21
HK1046863B (zh) 2008-07-25
RU2003132054A (ru) 2005-04-20
ZA200105016B (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
ATE322902T1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
MXPA02001099A (es) Compuestos para modular el receptor rage.
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2002078639A3 (fr) Traitement de maladies proliferatives au moyen d'inhibiteurs de eg5
EP1098642A4 (fr) Methodes de traitement d'etats modules par la lactosylceramide
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
HK1059439A1 (en) Compounds having activity as inhibitors of cytochrome p450rai
TNSN07372A1 (en) Method of treating or preventing type - 2 diabetes
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
SE9702993D0 (sv) Anti-mikrobial komposition
ATE422668T1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme
UA32167A (uk) Спосіб прогнозування появи негативної реакції крові при плануванні магнітотерапії, лазеротерапії, увч-терапії у хворих з травматичним переломом та остеомієлітом нижньої щелепи
NO994394L (no) Aktivert vitamin K-avhengig blodfaktor og fremgangsmÕte for fremstilling av denne